Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

Rhea-AI Summary

Nordic Nanovector ASA announced the allocation of restricted stock units (RSUs) to its board of directors as detailed in a previous stock exchange notice from June 2, 2021. The move is part of the company's commitment to align the interests of its directors with those of shareholders. The company is focused on developing innovative therapies for cancer care, notably its lead candidate Betalutin®, targeting non-Hodgkin's lymphoma, a market projected to reach nearly USD 26 billion by 2028. This strategic decision aims to enhance leadership commitment and support future growth.

Positive

• Alignment of directors' interests with shareholders through RSU allocation
• Focused on innovative cancer therapies, particularly Betalutin®
• Potential growth in a significant market projected to reach USD 26 billion by 2028

Negative

• None.

OSLO, Norway, June 18, 2021 /PRNewswire/ -- Reference is made to the stock exchange notice published 2 June 2021 regarding allocation of restricted stock units to members of the board of directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company").

Primary insider notifications for the same already notified transactions pursuant to the Market Abuse Regulation article 19 are attached hereto.

For further information, please contact:
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Market Abuse Regulation article 19 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--allocation-of-restricted-stock-units--rsus--to-the-board-of-directors,c3370456

The following files are available for download:

https://mb.cision.com/Main/9819/3370456/1434167.pdf

NANOV - Primary insider notifications June 2021 - Grant of RSUs

 

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-allocation-of-restricted-stock-units-rsus-to-the-board-of-directors-301315522.html

SOURCE Nordic Nanovector

FAQ

What does the RSU allocation mean for Nordic Nanovector (NRNVF)?

The RSU allocation aligns the interests of the board of directors with shareholders, potentially enhancing commitment to the company's growth.

When was the allocation of RSUs to Nordic Nanovector's board announced?

The allocation was announced on June 18, 2021, following a prior notice on June 2, 2021.

What is Nordic Nanovector's lead clinical-stage candidate?

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, designed to treat non-Hodgkin's lymphoma.

What is the expected market value for non-Hodgkin's lymphoma therapies by 2028?

The market for non-Hodgkin's lymphoma therapies is projected to be nearly USD 26 billion by 2028.